Middle East and Africa next generation sequencing (NGS) market is projected to register a CAGR of 11.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
Middle East and Africa Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables and Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research and Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes and Hospital & Clinics), Country (South Africa, Egypt, Saudi Arabia, U.A.E, Israel and Rest of Middle East And Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Middle East and Africa next generation sequencing (NGS) market are:
Rising research in the areas of genetic diseases such as Parkinson's disease (PD)
Growing number of biotechnology sequencing companies
High number of research employees
Market Players:
The key market players for Middle East and Africa next generation sequencing (NGS) market are listed below:
Thermo Fisher Scientific Inc.
QIAGEN
Illumina, Inc.
Bio-Rad Laboratories, Inc.
Roche Sequencing (A subsidiary of F. Hoffman La Roche)
BGI (A subsidiary of BGI Group)
Oxford Nanopore Technologies plc
Takara Bio Inc.
bioMrieux SA
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PESTEL'S ANALYSIS
3.2 PORTER'S FIVE FORCES MODEL
4 REGULATIONS OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 DECREASE IN THE COST OF GENETIC SEQUENCING PER BASE
5.1.2 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY
5.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER
5.1.4 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT
5.1.5 INCREASED TREND TOWARDS PERSONALIZED MEDICATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENT
5.2.2 DIFFICULTY IN CLINICAL NGS DATA ANALYSIS
5.2.3 CYBER SECURITY CONCERN IN GENOMICS
5.3 OPPORTUNITIES
5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
5.3.2 PRODUCT APPROVAL IN RECENT YEARS
5.3.3 ADVANCEMENT IN NGS TECHNOLOGY
5.4 CHALLENGES
5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS
5.4.2 CHALLENGES FOR IMPLEMENTING NGS IN THE CLINICAL LAB
6 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) HEALTHCARE INDUSTRY
6.1 IMPACT ON PRICE
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
6.5 CONCLUSION
7 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 HISEQ SERIES
7.2.2 MISEQ SERIES
7.2.3 ION TORRENT
7.2.4 PACBIO RS II
7.2.5 SEQUEL SYSTEM
7.2.6 SOLID
7.2.7 OTHERS
7.3 CONSUMABLE
7.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
7.3.2 SAMPLE PREPARATION CONSUMABLES
7.3.3 OTHERS
7.4 SERVICES
7.4.1 SEQUENCING SERVICES
7.4.2 DATA MANAGEMENT
8 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DIAGNOSTICS
8.3 BIOMARKER DISCOVERY
8.4 PRECISION MEDICINE
8.5 DRUG DISCOVERY
8.6 AGRICULTURE & ANIMAL RESEARCH
9 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 RESEARCH CENTERS & ACADEMIC AND GOVERNMENT INSTITUTES
9.4 HOSPITAL & CLINICS
10 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION
10.1 MIDDLE EAST AND AFRICA
10.1.1 SOUTH AFRICA
10.1.2 REST OF MIDDLE EAST AND AFRICA
11 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 COMPANY PROFILING
12.1 ILLUMINA, INC.
12.1.1 COMPANY SNAPSHOT
12.1.2 REVENUE ANALYSIS
12.1.3 COMPANY SHARE ANALYSIS
12.1.4 SWOT ANALYSIS
12.1.5 PRODUCT PORTFOLIO
12.1.6 RECENT DEVELOPMENTS
12.2 BGI (A SUBSIDIAIRY OF BGI GROUP) (2021)
12.2.1 COMPANY SNAPSHOT
12.2.2 REVENUE ANALYSIS
12.2.3 COMPANY SHARE ANALYSIS
12.2.4 SWOT ANALYSIS
12.2.5 PRODUCT PORTFOLIO
12.2.6 RECENT DEVELOPMENT
12.3 THERMO FISHER SCIENTIFIC INC.
12.3.1 COMPANY SNAPSHOT
12.3.2 REVENUE ANALYSIS
12.3.3 COMPANY SHARE ANALYSIS
12.3.4 SWOT ANALYSIS
12.3.5 PRODUCT PORTFOLIO
12.3.6 RECENT DEVELOPMENTS
12.4 QIAGEN
12.4.1 COMPANY SNAPSHOT
12.4.2 REVENUE ANALYSIS
12.4.3 COMPANY SHARE ANALYSIS
12.4.4 SWOT ANALYSIS
12.4.5 PRODUCT PORTFOLIO
12.4.6 RECENT DEVELOPMENTS
12.5 AGILENT TECHNOLOGIES, INC.
12.5.1 COMPANY SNAPSHOT
12.5.2 REVENUE ANALYSIS
12.5.3 COMPANY SHARE ANALYSIS
12.5.4 SWOT ANALYSIS
12.5.5 PRODUCT PORTFOLIO
12.5.6 RECENT DEVELOPMENT
12.6 OXFORD NANOPORE TECHNOLOGIES
12.6.1 COMPANY SNAPSHOT
12.6.2 PRODUCT PORTFOLIO
12.6.3 RECENT DEVELOPMENTS
12.7 BIO-RAD LABORATORIES, INC.
12.7.1 COMPANY SNAPSHOT
12.7.2 REVENUE ANALYSIS
12.7.3 PRODUCT PORTFOLIO
12.7.4 RECENT DEVELOPMENTS
12.8X GENOMICS
12.8.1 COMPANY SNAPSHOT
12.8.2 REVENUE ANALYSIS
12.8.3 PRODUCT PORTFOLIO
12.8.4 RECENT DEVELOPMENTS
12.9 BIOMRIEUX SA
12.9.1 COMPANY SNAPSHOT
12.9.2 REVENUE ANALYSIS
12.9.3 PRODUCT PORTFOLIO
12.9.4 RECENT DEVELOPMENT
12.10 DNASTAR
12.10.1 COMPANY SNAPSHOT
12.10.2 PRODUCT PORTFOLIO
12.10.3 RECENT DEVELOPMENT
12.11 GENEIOUS
12.11.1 COMPANY SNAPSHOT
12.11.2 PRODUCT PORTFOLIO
12.11.3 RECENT DEVELOPMENTS
12.12 GENEWIZ, FROM AZENTA LIFE SCIENCES
12.12.1 COMPANY SNAPSHOT
12.12.2 REVENUE ANALYSIS
12.12.3 PRODUCT PORTFOLIO
12.12.4 RECENT DEVELOPMENTS
12.13 HAMILTON COMPANY
12.13.1 COMPANY SNAPSHOT
12.13.2 PRODUCT PORTFOLIO
12.13.3 RECENT DEVELOPMENT
12.14 MACROGEN, INC.
12.14.1 COMPANY SNAPSHOT
12.14.2 REVENUE ANALYSIS
12.14.3 PRODUCT PORTFOLIO
12.14.4 RECENT DEVELOPMENT
12.15 NEW ENGLAND BIOLABS
12.15.1 COMPANY SNAPSHOT
12.15.2 PRODUCT PORTFOLIO
12.15.3 RECENT DEVELOPMENT
12.16 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
12.16.1 COMPANY SNAPSHOT
12.16.2 REVENUE ANALYSIS
12.16.3 PRODUCT PORTFOLIO
12.16.4 RECENT DEVELOPMENTS
12.17 PARTEK, INCORPORATED
12.17.1 COMPANY SNAPSHOT
12.17.2 PRODUCT PORTFOLIO
12.17.3 RECENT DEVELOPMENT
12.18 PERKIN ELMER INC. (2021)
12.18.1 COMPANY SNAPSHOT
12.18.2 REVENUE ANALYSIS
12.18.3 PRODUCT PORTFOLIO
12.18.4 RECENT DEVELOPMENTS
12.19 ROCHE SEQUENCING (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
12.19.1 COMPANY SNAPSHOT
12.19.2 REVENUE ANALYSIS (PARENT COMPANY)
12.19.3 PRODUCT PORTFOLIO
12.19.4 RECENT DEVELOPMENTS
12.20 TAKARA BIO INC.
12.20.1 COMPANY SNAPSHOT
12.20.2 REVENUE ANALYSIS
12.20.3 PRODUCT PORTFOLIO
12.20.4 RECENT DEVELOPMENTS
13 QUESTIONNAIRE
14 RELATED REPORTS
Segmentation
Short Description
Middle East and Africa Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables and Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research and Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes and Hospital & Clinics), Country (South Africa, Egypt, Saudi Arabia, U.A.E, Israel and Rest of Middle East And Africa) Industry Trends and Forecast to 2029
Market Definition:
Next generation sequencing or NGS is also known as high-throughput sequencing. It is an exceptional technology which arranges massive DNA strands through huge parallelization. The breakthrough reduces the need for segment cloning that is used in Sanger genome sequencing. The main benefits that NGS provides over Sanger's sequencing methodology are fast procedures, precise performance, and organizational ease even from small sample data. With the development of new technologies and cancer cure treatment, the next-generation sequencing market in clinical oncology has huge potential in the coming years.
Market Segmentation:
Middle East and Africa next generation sequencing (NGS) market is categorized into three notable segments such as product, applications, and end user.
On the basis of product, the Middle East and Africa next generation sequencing (NGS) market is segmented into instruments, consumables and services
On the basis of application, the Middle East and Africa next generation sequencing (NGS) market is segmented into diagnostics, biomarker discovery, precision medicine, drug discovery, agriculture and animal research and others
On the basis of end-users, the Middle East and Africa next generation sequencing (NGS) market is segmented into pharmaceutical & biotechnology companies, research centers & academic and government institutes and hospital & clinics
Market Players
The key market players for Middle East and Africa next generation sequencing (NGS) market are listed below:
Thermo Fisher Scientific Inc.
QIAGEN
Illumina, Inc.
Bio-Rad Laboratories, Inc.
Roche Sequencing (A subsidiary of F. Hoffman La Roche)
BGI (A subsidiary of BGI Group)
Oxford Nanopore Technologies plc
Takara Bio Inc.
bioMrieux SA
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
